List of Excipients in Branded Drug FLANAX PAIN RELIEVER

« Back to Dashboard

Generic Drugs Containing FLANAX PAIN RELIEVER

Company	Ingredient	NDC	Excipient
Belmora LLC	naproxen sodium	27854-103	CROSCARMELLOSE SODIUM
Belmora LLC	naproxen sodium	27854-103	FD&C BLUE NO. 2
Belmora LLC	naproxen sodium	27854-103	MAGNESIUM STEARATE
Belmora LLC	naproxen sodium	27854-103	POLYETHYLENE GLYCOL
Belmora LLC	naproxen sodium	27854-103	POLYVINYL ALCOHOL
Belmora LLC	naproxen sodium	27854-103	POVIDONE

What are the Most Frequently-Used Excipients in FLANAX PAIN RELIEVER?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	FD&C BLUE NO. 2
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL
1	POLYVINYL ALCOHOL
1	POVIDONE

Flanax Pain Reliever Excipient Strategy and Commercial Opportunities

Last updated: October 16, 2026

Flanax Pain Reliever is an over-the-counter naproxen sodium product, generally marketed at 220 mg per tablet or caplet. Its commercial position depends on low-cost tablet manufacture, rapid disintegration, product stability, recognizable branding, and broad retail distribution rather than on active-ingredient patent protection. Naproxen sodium has a mature generic market, and the main commercial opportunities are differentiated dosage forms, private-label supply, regional expansion, and formulation improvements that remain compliant with the FDA OTC monograph.

What drug and dosage form does Flanax Pain Reliever contain?

The standard U.S. presentation contains naproxen sodium 220 mg, equivalent to 200 mg naproxen. It is an oral nonsteroidal anti-inflammatory drug used for temporary relief of minor aches and pains and reduction of fever. The product is subject to OTC NSAID labeling and dosage requirements under FDA regulations.[1]

Attribute	Flanax Pain Reliever
Active ingredient	Naproxen sodium
Typical strength	220 mg per tablet or caplet
Naproxen equivalent	200 mg
Drug class	NSAID
Primary indications	Temporary relief of minor aches and pains; fever reduction
Typical OTC dose	One tablet every 8 to 12 hours
Maximum adult daily dose	Three tablets in 24 hours unless directed by a physician
Primary dosage form	Immediate-release tablet or caplet
Prescription status	OTC in the United States
FDA pathway	OTC monograph compliance rather than a new molecular entity approval

The exact Flanax presentation and inactive-ingredient list can vary by country, package size, manufacturer, and manufacturing site. A commercial assessment should therefore distinguish the U.S. label from Mexican, Latin American, and private-label versions.

What excipients are used in Flanax Pain Reliever?

Publicly marketed naproxen sodium tablets commonly use a conventional direct-compression or wet-granulation excipient system. Typical components include microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, talc, silicon dioxide, and film-coating materials such as hypromellose, polyethylene glycol, titanium dioxide, and approved colorants. The current product label and FDA Inactive Ingredient Database control the relevant regulatory assessment.[2][3]

Functional role of the excipients

Excipient category	Typical function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and low-cost manufacturing
Croscarmellose sodium	Superdisintegrant	Helps offset naproxen sodium’s relatively high tablet loading
Povidone	Binder	Improves granule strength and reduces friability
Magnesium stearate	Lubricant	Supports tablet ejection but can slow wetting if overused
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and blend uniformity
Talc	Anti-adherent and processing aid	Supports tooling performance and surface quality
Hypromellose	Film former	Protects the tablet and improves swallowability
Polyethylene glycol	Plasticizer	Reduces coating brittleness
Titanium dioxide or colorants	Opacifier and brand identification	Supports product recognition and light protection

The excipient strategy is principally a manufacturing strategy. The goal is to produce a robust immediate-release tablet with acceptable disintegration, low friability, consistent naproxen sodium content, and stable appearance across the product shelf life.

How should an excipient strategy address naproxen sodium?

Naproxen sodium is more water-soluble than naproxen, which supports immediate-release performance. The formulation still requires careful control of tablet hardness, lubricant concentration, particle-size distribution, and moisture exposure.

A high-value excipient strategy would focus on four performance targets:

1. Consistent disintegration after compression and film coating.
2. Rapid dissolution across the applicable FDA dissolution conditions.
3. Low sensitivity to humidity and temperature during storage.
4. Efficient high-speed tableting with limited sticking and capping.

Compression and disintegration

The active ingredient represents a substantial portion of the tablet mass. Excessive compression force or over-lubrication can delay disintegration. Croscarmellose sodium or another suitable superdisintegrant can improve tablet breakup, but performance depends on concentration, intra-granular versus extra-granular placement, and the manufacturing process.

A formulation using a portion of the superdisintegrant inside the granule and the balance outside the granule may provide a practical balance between tablet strength and rapid disintegration. Direct compression can reduce processing steps, but it requires consistent raw-material flow and compressibility.

Lubrication

Magnesium stearate is commercially attractive because it is inexpensive and widely accepted. Its level and blending time require control. Excessive lubrication can reduce tablet tensile strength and slow wetting. Alternative lubricants, including sodium stearyl fumarate, may provide a development path for faster wetting or improved processing, although the cost and regulatory justification may be less favorable.

Film coating

A thin hypromellose-based coating can improve swallowability and reduce dusting without materially delaying dissolution. Coating weight should remain controlled because naproxen sodium tablets do not require an extended-release barrier. Color and opacity can support product recognition, but colorants add supply-chain and regional regulatory complexity.

Moisture and packaging

Moisture protection is a practical commercial differentiator. The preferred packaging configuration depends on distribution conditions and target markets:

Packaging option	Advantages	Limitations
High-density polyethylene bottle	Low unit cost; efficient for large packs	Less convenient for travel; moisture ingress depends on closure and desiccant
Blister pack	Dose integrity and portability	Higher packaging cost
Aluminum-aluminum blister	Strong moisture and light barrier	Higher material and equipment cost
Unit-dose pouch	Suitable for convenience channels	More complex packaging validation
Child-resistant bottle	Supports U.S. compliance and household safety	Adds closure cost and consumer friction

A regional strategy may use bottles for value channels and high-barrier blisters for hot, humid markets or e-commerce shipments.

What formulation patents protect Flanax Pain Reliever?

No meaningful active-ingredient patent barrier is expected for conventional naproxen sodium immediate-release tablets. Naproxen and naproxen sodium have been generic products for decades. The commercial product is therefore exposed to competition from store brands, authorized generics, private-label manufacturers, and other branded NSAIDs.

Potentially protectable subject matter would relate to:

• A novel chewable or orally disintegrating dosage form.
• A taste-masked liquid or suspension.
• A specific excipient ratio that improves dissolution or stability.
• A moisture-resistant coating or packaging system.
• A fixed-dose combination with another OTC active ingredient.
• A manufacturing process that reduces impurities or improves yield.
• A differentiated delivery system, such as a liquid-filled softgel.

A routine combination of naproxen sodium with standard excipients would have limited patent strength. Patentability would depend on unexpected technical results, a defined formulation range, superior stability, improved dissolution, or a clinically relevant usability advantage. Trade-secret protection may be more practical for process parameters, coating conditions, blend order, and packaging controls.

What is the Orange Book status of Flanax Pain Reliever?

Flanax Pain Reliever is generally positioned as an OTC monograph product rather than an NDA-listed prescription product. The Orange Book is therefore not the principal source of exclusivity for the standard product.[4]

Regulatory issue	Assessment
New chemical entity exclusivity	Not applicable
Prescription NDA exclusivity	Not expected for the standard OTC presentation
Orange Book patent listing	Not expected to be the principal protection mechanism
Paragraph IV certification	Generally relevant to ANDAs, not to a conventional OTC monograph product
FDA monograph compliance	Central regulatory pathway
Labeling control	FDA Drug Facts and applicable NSAID requirements
Generic competition	High

A reformulated product that requires an NDA or other FDA approval could create a different regulatory profile, but the ordinary 220 mg immediate-release tablet does not depend on a long-lived regulatory exclusivity period.

When does Flanax lose exclusivity?

Flanax has no practical exclusivity period tied to the naproxen sodium molecule. Generic and private-label competition can enter under applicable OTC requirements, subject to manufacturing, labeling, trademark, and distribution considerations.

The relevant commercial timeline is therefore:

Event	Timing or status
Naproxen sodium active ingredient	Long off-patent
Conventional immediate-release tablet	Mature generic category
FDA OTC monograph route	Available subject to compliance
Brand trademark protection	Potentially ongoing, but separate from drug exclusivity
Formulation patent protection	Depends on any specific proprietary formulation
Generic launch timing	Primarily driven by manufacturing, regulatory, and commercial readiness

The Flanax trademark may protect brand identity in particular jurisdictions, but trademark rights do not prevent lawful sales of competing naproxen sodium products under different names.

What generic entry risks exist for Flanax?

Generic entry risk is high because the product has a simple dosage form, a well-characterized active ingredient, widely available excipients, and numerous contract manufacturers capable of producing comparable tablets.

The principal competitive risks are:

• Store-brand naproxen sodium sold at lower prices.
• Large-chain pharmacy private labels.
• Amazon and e-commerce private-label products.
• Regional brands in Mexico and Latin America.
• Competing ibuprofen and acetaminophen products.
• Value packs with lower per-dose pricing.
• Softgel and liquid-filled formats marketed as easier to swallow.

The strongest defenses are brand recognition, distribution access, consistent quality, compliant labeling, and packaging convenience. An excipient system by itself is unlikely to prevent substitution.

Which companies are challenging Flanax commercially?

The competitive set includes manufacturers and retailers selling naproxen sodium 220 mg, including:

• Bayer-branded Aleve and related products.
• Generic manufacturers such as Perrigo, Dr. Reddy’s, Teva, and other regional suppliers.
• Retail private-label operators, including major U.S. pharmacy, supermarket, warehouse, and mass-retail chains.
• Latin American pharmaceutical companies marketing naproxen sodium under local brands.
• Manufacturers of ibuprofen and acetaminophen products competing for the same pain-relief purchase.

Competition is usually based on price, pack size, retailer placement, product recognition, and consumer preference. Patent litigation is unlikely to be the central competitive mechanism for conventional Flanax tablets.

What commercial opportunities exist for Flanax excipient innovation?

Fast-dissolving and easy-swallow tablets

A thinner tablet, smoother film coating, or orally disintegrating format could target consumers who have difficulty swallowing conventional caplets. The formulation must preserve dose uniformity, acceptable taste, and regulatory compliance.

Chewable naproxen sodium

A chewable product could expand use among consumers who prefer not to swallow tablets. Taste masking is the principal technical challenge. Suitable approaches may include polymer coating, ion-exchange resins, sweetener systems, flavors, and controlled particle-size engineering.

Liquid and suspension products

A naproxen sodium suspension could target pediatric or dysphagia markets, although dosing accuracy, sedimentation, preservative selection, taste, and NSAID safety labeling create greater development complexity. Pediatric positioning would require particular regulatory and clinical care.

Softgel or liquid-filled capsule

A liquid-filled capsule can offer a differentiated appearance and swallowability profile. Its commercial value would depend on demonstrable consumer preference, manufacturing economics, and dissolution performance. It would compete against established liquid-filled NSAID products.

Combination products

Potential combinations include naproxen sodium with acetaminophen or other OTC actives. Combination products create opportunities for higher retail pricing and specific indication claims, but they also increase labeling complexity, dose-management concerns, safety review, and patent risk.

Premium packaging

A high-barrier blister, calendar pack, travel pack, or individually wrapped tablet can support premium positioning without changing the active ingredient. Packaging improvements may generate a faster commercial return than a new formulation.

Private-label and licensing supply

The strongest near-term opportunity may be contract manufacturing and private-label supply. A manufacturer with validated naproxen sodium processes, reliable raw-material sourcing, and multiple packaging formats could supply drugstores, supermarkets, warehouse clubs, convenience retailers, and e-commerce sellers.

How strong is the patent estate for Flanax?

The patent estate is weak for the conventional product and potentially moderate for a genuinely differentiated delivery system.

Asset type	Likely strength
Naproxen sodium composition	Very weak or expired
Conventional 220 mg tablet	Very weak
Standard excipient combination	Weak unless supported by unexpected results
Film-coating system	Weak to moderate
Moisture-barrier packaging	Moderate if technically novel
Chewable or orally disintegrating format	Moderate, depending on claims and data
Combination product	Moderate to strong if claims are specific and supported
Manufacturing process	Moderate if difficult to design around
Trademark and trade dress	Potentially meaningful commercially
Manufacturing know-how	Often more valuable than patents

A defensible formulation patent should claim narrow, measurable technical features rather than generic use of known excipients. Useful evidence would include comparative dissolution, stability, tablet-strength, friability, and manufacturability data against a conventional formulation.

What licensing deals could support Flanax growth?

Licensing opportunities are more likely to involve brands, distribution, manufacturing, or regional rights than the naproxen sodium molecule. Relevant deal structures include:

• Regional trademark licensing for Flanax.
• Contract manufacturing and supply agreements.
• Private-label production using the same validated platform.
• Co-development of chewable, softgel, or liquid presentations.
• Retailer-exclusive pack sizes.
• Technology licensing for high-barrier packaging.
• Distribution agreements for Mexico, Central America, and selected Asian markets.

A licensee would typically seek rights to the brand, formulation dossier, regulatory files, manufacturing specifications, artwork, and approved suppliers. A manufacturer may prefer a supply agreement that preserves process know-how as a trade secret rather than assigning formulation patents.

What manufacturing and IP barriers affect commercialization?

The active ingredient is widely available, so manufacturing barriers are limited. The practical barriers are quality-system execution and supply-chain reliability.

Key controls include:

• Naproxen sodium particle size and polymorphic consistency.
• Blend uniformity at commercial batch scale.
• Lubrication time and tablet ejection force.
• Dissolution after coating and accelerated aging.
• Impurity and degradation-product control.
• Colorant and coating-material availability.
• Child-resistant packaging performance.
• Stability in hot and humid distribution environments.
• FDA-compliant Drug Facts labeling.
• Supplier qualification and change control.

The most valuable proprietary knowledge may involve tooling, compression settings, coating parameters, packaging specifications, and raw-material acceptance criteria. These controls can reduce cost and batch failure risk even when they do not create a strong patent position.

What is the revenue exposure for Flanax?

Publicly attributable revenue for Flanax Pain Reliever is generally not disclosed separately from broader company or regional OTC portfolios. Revenue exposure should therefore be modeled using unit volume, average net selling price, channel mix, and geographic distribution rather than relying on a standalone public brand figure.

A practical commercial model should include:

Variable	Sensitivity
Unit volume	High
Retail price	High
Private-label substitution	High
Retailer margin	High
Packaging format	Moderate
Brand investment	Moderate
Raw-material cost	Moderate
Excipient cost	Low to moderate
Regulatory changes	Market-specific
Product recalls or quality failures	Potentially severe

Excipient costs are usually a small portion of total retail value. The larger financial impact comes from manufacturing yield, packaging, freight, trade promotion, retailer discounts, and brand placement.

How does Flanax compare with other OTC pain relievers?

Product category	Active ingredient	Typical advantage	Main commercial weakness
Flanax	Naproxen sodium	Longer dosing interval than some alternatives	NSAID gastrointestinal, renal, and cardiovascular warnings
Aleve and other naproxen brands	Naproxen sodium	Strong brand recognition	Higher price than private label
Advil and generic ibuprofen	Ibuprofen	Broad consumer familiarity and multiple formats	More frequent dosing for some users
Tylenol and generic acetaminophen	Acetaminophen	Non-NSAID positioning	Liver toxicity warnings and different efficacy profile
Aspirin products	Aspirin	Low cost and established use	Bleeding risk and narrower consumer suitability

Flanax’s primary commercial differentiation is naproxen sodium’s established consumer positioning and longer dosing interval. Excipients can improve usability, but they do not materially change the core therapeutic identity.

Key Takeaways

• Flanax Pain Reliever is a mature OTC naproxen sodium product, typically supplied as a 220 mg immediate-release tablet or caplet.
• The conventional product has little meaningful active-ingredient or formulation exclusivity.
• A standard excipient system should prioritize rapid disintegration, stable dissolution, compression efficiency, moisture control, and low manufacturing cost.
• The most attractive formulation opportunities are chewable, orally disintegrating, liquid-filled, liquid, and premium-packaged products.
• Private-label supply, regional licensing, and retailer-specific packaging may offer stronger commercial returns than a conventional new tablet.
• FDA OTC monograph compliance, Drug Facts labeling, and NSAID warnings are central to commercialization.
• Paragraph IV litigation and Orange Book exclusivity are unlikely to drive the standard Flanax business.
• Trade secrets covering process parameters and packaging may have greater practical value than broad excipient patents.
• Generic and private-label substitution risk is high.
• Separate Flanax revenue is generally not publicly reported, so commercial valuation requires a unit-volume and channel-based model.

FAQs

Is Flanax the same as naproxen sodium?

Yes. The standard Flanax Pain Reliever product contains naproxen sodium, commonly at a 220 mg tablet strength equivalent to 200 mg naproxen.

Can Flanax be reformulated as an orally disintegrating tablet?

Yes, but the formulation would require taste masking, dose uniformity, acceptable mouthfeel, rapid disintegration, and compliant dissolution and labeling data.

Are excipients in Flanax protected by patents?

Standard excipients such as microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate are not proprietary to Flanax. A narrowly defined formulation or process could receive patent protection if it demonstrated novelty and unexpected technical results.

Is Flanax subject to biosimilar competition?

No. Naproxen sodium is a small-molecule drug, not a biologic. The relevant competition is from generic, private-label, and branded NSAID products.

What is the best commercial extension for Flanax?

A high-barrier travel blister, chewable tablet, orally disintegrating tablet, or softgel could create more differentiation than another conventional immediate-release caplet. Private-label manufacturing and regional licensing are also commercially attractive.

References

1. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 343.50: Professional labeling of internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.
2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. National Library of Medicine. (2024). DailyMed: Flanax Pain Reliever, naproxen sodium tablet labeling. https://dailymed.nlm.nih.gov/dailymed/
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda